- Conditions
- Vaginal Infection
- Interventions
- Metronidazole, Gel vehicle
- Drug
- Lead sponsor
- Curatek Pharmaceuticals, LLC
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2521–2544
of 12,244
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsed/Refractory Aggressive B-Cell Malignancies
- Interventions
- ONCT-808, Bridging Therapy
- Biological · Drug
- Lead sponsor
- Oncternal Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Duarte, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Velcade, Thalidomide, and Dexamethasone, Velcade, Melphalan, and Dexamethasone
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- COVID-19
- Interventions
- PUL-042 Inhalation Solution, Placebo
- Drug
- Lead sponsor
- Pulmotect, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 11
- States / cities
- Orange, California • San Bernardino, California • Coral Gables, Florida + 7 more
- Conditions
- Acute Myeloid Leukemia, in Relapse, MDS
- Interventions
- MT-401-OTS
- Drug
- Lead sponsor
- Marker Therapeutics, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Duarte, California • Tampa, Florida • Kansas City, Kansas
- Conditions
- Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- Peripheral Blood Stem Cell Transplantation
- Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Modified Atkins diet
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Actinic Keratosis (AK)
- Interventions
- 5-FU Cream, Efudex®, Vehicle
- Drug
- Lead sponsor
- Sol-Gel Technologies, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cerritos, California
- Conditions
- Epilepsy
- Interventions
- Compliance
- Behavioral
- Lead sponsor
- Orlando Health, Inc.
- Other
- Eligibility
- 16 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Multiple Myeloma
- Interventions
- Siltuximab11 mg/kg, Siltuximab 8.3 mg/kg or 11 mg/kg, Velcade (bortezomib), Melphalan, Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
- Conditions
- Neoplasm Metastasis
- Interventions
- PF-07265807, Sasanlimab, Axitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 25
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- ACZ885, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Albany, New York • Cleveland, Ohio
- Conditions
- Papillomavirus Infections
- Interventions
- 851B
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more
- Conditions
- Child Obesity, Nutrition, Healthy
- Interventions
- Healthy Eating: Provider and Parent Components, Healthy Start: Reading Readiness Childcare Proiver and Parent Materials
- Behavioral
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Obesity
- Interventions
- S-309309, Midazolam, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- bortezomib, tipifarnib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- HIV, Substance Use Disorder (SUD), Injection Drug Use
- Interventions
- APRETUDE (cabotegravir)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
- Interventions
- Administration of autologous adipose derived SVF
- Procedure
- Lead sponsor
- Elliot Lander
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Rancho Mirage, California
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- KITE-585, Cyclophosphamide, Fludarabine
- Genetic · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Multiple Myeloma
- Interventions
- CC-99712, BMS-986405
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 7
- States / cities
- La Jolla, California • Sarasota, Florida • Buffalo, New York + 4 more
- Conditions
- Multiple Sclerosis, Fatigue
- Interventions
- High Dose Aspirin (1300 mg/day), Low Dose Aspirin (162 mg/day), Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blastic Phase, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Disease
- Interventions
- Cyclosporine, Dasatinib, Fludarabine Phosphate, Imatinib Mesylate, Mycophenolate Mofetil, Nilotinib, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Therapeutic Allogeneic Lymphocytes, Total-Body Irradiation
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2018
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Seattle, Washington
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Fingolimod
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 60 more
- Conditions
- Alzheimers Disease, AD
- Interventions
- [F18] T807
- Radiation
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Irvine, California • Los Angeles, California